Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00134069
Other study ID # NCI-2009-00110
Secondary ID 07-0571R21CA1171
Status Completed
Phase Phase 1
First received August 22, 2005
Last updated April 15, 2014
Start date June 2005
Est. completion date December 2011

Study information

Verified date April 2014
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase I/II trial is studying the side effects and best dose of sorafenib when given together with cetuximab and irinotecan and to see how well they work in treating patients with advanced or metastatic colorectal cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Sorafenib and cetuximab may also stop tumor growth by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to kill tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with cetuximab and irinotecan may kill more tumor cells


Description:

OBJECTIVES:

I. Determine the toxicity spectrum and dose-limiting toxic effects of sorafenib when combined with cetuximab and irinotecan in patients with advanced or metastatic colorectal cancer.

II. Determine the recommended phase II dose of sorafenib when combined with cetuximab and irinotecan in these patients.

III. Correlate the clinical activity of this regimen, in terms of radiologic and positron emission tomography (PET) response, with baseline extracellular signal-regulated kinase (ERK) expression as well as Kirsten rat sarcoma (KRAS), BRAF, and other genetic properties of tumors in these patients.

IV. Determine the pharmacokinetics of this regimen in these patients. V. Correlate the pharmacodynamic effects of this regimen with baseline ERK expression as well as KRAS, BRAF, and other genetic properties of tumors in these patients.

VI. Correlate the pharmacodynamic effects of this regimen on mitogen-activated protein kinase (MAPK) status in peripheral blood mononuclear cells and on normal skin and oral mucosa with clinical parameters in these patients.

OUTLINE: This is a phase I dose-escalation study of sorafenib followed by a multicenter phase II study.

PHASE I:

COURSE 1 (56 days): Patients receive oral sorafenib once or twice daily on days 1-56, cetuximab IV over 1-2 hours on days 1, 8,15, 22, 29, 36, 43, and 50, and irinotecan IV over 90 minutes on days 15, 22, 29, and 36.

COURSE 2 AND ALL SUBSEQUENT COURSES (42 days): Patients receive oral sorafenib once or twice daily on days 1-42, cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36, and irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of sorafenib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.

PHASE II: Patients receive sorafenib at the MTD determined in phase I, cetuximab, and irinotecan as in phase I.

After completion of study treatment, patients are followed at 30 days.

*NOTE: This trial was intended to be Phase I/II, but the trial never continued to the Phase II portion.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date December 2011
Est. primary completion date September 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically or cytologically confirmed colorectal cancer (advanced or metastatic disease not amenable to potential curative resection)

- Archival tumor (blocks and/or slides) must be available for patients who decline tumor biopsies

- Tumor must be amenable to sequential biopsies for patients willing to undergo tumor biopsy

- Must have evidence of disease progression after first-line chemotherapy for advanced disease

- Previously irradiated lesions are not considered measurable disease

- Measurable disease, defined as >= 1 unidimensionally measurable target lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan

- No known brain metastases

- Eastern Cooperative Oncology Group (ECOG) 0-2 OR Karnofsky 60-100%

- Life expectancy of more than 12 weeks

- white blood cell count (WBC) >= 3,000/mm^3

- Bilirubin normal

- Creatinine normal OR creatinine clearance >= 60 mL/min

- No hypertension

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No cardiac arrhythmia

- Not pregnant or nursing

- Able to swallow oral medication

- Willing to undergo 2 sequential tumor and skin biopsies

- No ongoing or active infection

- No history of allergic reaction attributed to compounds of similar chemical or biologic composition to study drugs

- No psychiatric illness or social situation that would preclude study compliance

- No other uncontrolled illness

- No prior cetuximab

- No concurrent prophylactic filgrastim (G-CSF), sargramostim (GM-CSF) or epoetin alfa

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered

- No other concurrent chemotherapy

- More than 4 weeks since prior radiotherapy and recovered

- No prior sorafenib

- No other prior therapy targeted against MAPK

- More than 14 days since prior and no concurrent administration of the following cytochrome P450 3A4 (CYP3A4) inducers:

- Rifampin

- Rifabutin

- Hypericum perforatum (St. John's wort)

- Phenytoin

- Carbamazepine

- Phenobarbital

- More than 7 days since prior and no concurrent administration of the following CYP3A4 inhibitors:

- Amiodarone

- Clarithromycin

- Diltiazem

- Erythromycin

- Grapefruit juice

- Indinavir

- Saquinavir

- Lopinavir in combination with ritonavir

- Fosamprenavir

- Ritonavir

- Atazanavir

- Nelfinavir

- Itraconazole

- Ketoconazole

- Nefazodone

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No other concurrent investigational agents

- No other concurrent anticancer therapy

- Negative pregnancy test

- Fertile patients must use effective contraception

- Absolute neutrophil count >=1,500/mm^3

- Platelet count = 100,000/mm^3

- No evidence of bleeding diathesis

- Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) = 2.5 times upper limit of normal

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
sorafenib tosylate
Given orally
cetuximab
Given IV
irinotecan hydrochloride
Given IV

Locations

Country Name City State
United States University of Colorado at Denver Health Sciences Center Aurora Colorado
United States Johns Hopkins University Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicity spectrum and dose-limiting toxicities of sorafenib in combination with cetuximab and irinotecan as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v 3.0 Up to 30 days Yes
Primary Recommended dose for phase II evaluation of the combination of sorafenib, cetuximab and irinotecan 56 days No
Primary Clinical activity of the combination of sorafenib, cetuximab and irinotecan in terms of radiological response Up to 30 days No
Primary Pharmacokinetics of sorafenib, cetuximab, and irinotecan when given in combination or when given in combination with cetuximab alone and with cetuximab and irinotecan Up to 30 days No
Primary Pharmacodynamics of the combination of irinotecan when given in combination with sorafenib and cetuximab in tumor tissues Up to 30 days No
See also
  Status Clinical Trial Phase
Completed NCT01987726 - Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
Active, not recruiting NCT00826540 - Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT00025337 - Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated Phase 3
Recruiting NCT04642924 - SGM-101 in Locally Advanced and Recurrent Rectal Cancer Phase 2/Phase 3
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT01217450 - Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors Phase 1
Completed NCT01191684 - Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer Phase 1
Terminated NCT01285102 - Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer Phase 1
Terminated NCT01238965 - Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy Phase 1
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT01037790 - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Phase 2
Completed NCT00551421 - Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT00407654 - VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer Phase 2
Completed NCT00091182 - Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Phase 2
Terminated NCT00052585 - Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer Phase 2
Completed NCT00023933 - Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer Phase 1
Not yet recruiting NCT05076305 - PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
Completed NCT01740648 - Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer Phase 1
Terminated NCT00397878 - AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer Phase 2
Completed NCT00100841 - Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Phase 2